CURX
Curanex Pharmaceuticals Inc
Healthcare — Biotechnology
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. Curanex Pharmaceuticals Inc was founded in 1996 and is headquartered in Jericho, New York.
None
$4.98
$-0.05 (-1.00%)
Price History
52-Week Range
Sign in to add CURX to a watchlist or set price alerts.
Fundamentals
| Market Cap | $7.77M |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | $-0.02 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -85.25% |
| Debt/Equity | 155.99 |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 34.3 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $9.18 |
| 52-Week Low | $0.26 |
| 50-Day Avg | $0.33 |
| 200-Day Avg | $0.54 |
| Avg Volume | 14.2K |
| Volume | 24.1K |
Performance Analysis
NEUTRALCURX presents a mixed picture with both positive and negative indicators.
~
Trading at 53% of its 52-week range.
~
RSI at 34.3 is in neutral territory.
+
Price is above both the 50-day and 200-day moving averages — strong uptrend.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Jul 02, 2026 13:05 UTC
Back to Screener Export Report